Adocia SA Stocks

Adocia S.A. is a clinical-stage biotechnology firm that specializes in developing enhanced formulations of existing therapeutic proteins and peptides, primarily targeting diabetes and other metabolic disorders. The company leverages its unique BioChaperone technological platform, specifically designed to boost the performance of these therapeutic proteins. Its robust clinical pipeline showcases several advanced insulin formulations, including BioChaperone Lispro U100 and U200, which are ultra-rapid-acting versions of insulin lispro. Other key candidates are BioChaperone Combo, a blend of long-acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, which pairs prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous human glucagon formulation for managing hypoglycemia. M1Pram, a derivative combining insulin glargine and pramlintide, is also under clinical investigation. In its earlier preclinical development phases, Adocia is advancing bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a fixed-dose pairing of insulin glargine with a GLP-1 receptor analogue. The preclinical portfolio also extends to multihormonal therapies for obesity, featuring BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a triple combination of pramlintide, glucagon, and exenatide. Adocia has established a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. to facilitate the development and commercialization of BioChaperone Lispro and BioChaperone Combo in China, as well as selected markets in Asia and the Middle East. The company was founded in 2005 and is headquartered in Lyon, France.